ENETS Abstract Search

64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast


Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.

Aim(s): We hypothesized that the PET/CT imaging time-window can be extended up to 3h pi of 64Cu-DOTATATE without reduction in the ability to detect lesions.

Materials and methods: From a prospective study, we compared head-to-head 64Cu-DOTATATE PET/CT images in NEN patients scanned at 1h and 3h pi. We compared lesion numbers and measured lesion maximal standardized uptake values (SUVmax) as well as normal tissue mean SUV (SUVmean). We calculated tumor-to-normal tissue ratios (TTN) from lesion SUVmax/normal tissue SUVmean. Discrepant findings were considered true lesions if found on simultaneous CT or later MR, CT or SRI. Data is presented as mean (standard error of mean) and analyzed with paired T-tests.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Loft M, Johannesen H, Carlsen E, Johnbeck C, Binderup T,

Keywords: 64Cu-DOTATATE, Neuroendocrine Neoplasms, PET Imaging, Somatostatin Receptor Imaging,

To read the full abstract, please log into your ENETS Member account.